Skip to main content

Table 2 Percentage of patients with at least one infection during the treatment period a

From: A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis

  n/N(%)
  60 mg (N = 60) 60 mg/120 mg (N = 121)
B cells, cells/μl   
>50% reduction 10/38 (26%) 29/66 (44%)
≤50% reduction 9/16 (56%) 21/42 (50%)
No reduction 3/5 (60%) 6/10 (60%)
Serum IgG   
≥5.65 g/L 22/58 (38%) 56/118 (48%)
<5.65 to ≥4.24 g/L 0/1 (0%) 2/2 (100%)
<4.24 g/L 0/0 (0%) 0/1 (0%)
Serum IgM   
≥0.40 g/L 22/57 (39%) 55/113 (49%)
<0.40 to ≥0.30 g/L 0/2 (0%) 1/4 (25%)
<0.30 g/L 0/0 (0%) 2/4 (50%)
Serum IgA   
≥ 0.70 g/L 22/59 (37%) 58/120 (48%)
<0.70 to ≥0.525 g/L 0/0 (0%) 0/0 (0%)
<0.525 g/L 0/0 (0%) 0/1 (0%)
  1. aIg, Immunoglobulin; n, Number of patients with at least one infection with analyte measurement in that category; N, Number of patients with analyte measurement in that category; RCT, Randomized control trial. For patients assigned to receive tabalumab in the first or second randomized controlled trial (RCT1 or RCT2, respectively) pretabalumab baseline data were collected at week 0 of RCT1 or RCT2. For patients assigned to receive placebo in RCT1 or RCT2, pretabalumab baseline data were collected either before receiving an optional 80-mg tabalumab rescue dose at week 16 in RCT1 or at the time of open-label extension study entry.